There have been no reports of overdosage with Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) in humans.
There have been no reports of overdosage with Ganirelix Acetate Organon Injection (ganirelix) in humans.
Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) is contraindicated under the following conditions:
Ganirelix Acetate Organon Injection (ganirelix) is contraindicated under the following conditions:
The safety of Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) was evaluated in two randomized, parallel-group, multicenter controlled clinical studies. Treatment duration for Ganirelix Acetate Organon Acetate ranged from 1 to 14 days. Table IV represents adverse events (AEs) from first day of Ganirelix Acetate Organon Acetate administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in Ganirelix Acetate Organon Acetate-treated subjects without regard to causality.
TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in Ganirelix Acetate Organon Acetate-treated subjects). Completed controlled clinical studies (All-subjects-treated group).
| Adverse Events Occurring in ≥ 1% | Ganirelix Acetate Organon Acetate N=794 % (n) |
| Abdominal Pain (gynecological) | 4.8 (38) |
| Death Fetal | 3.7 (29) |
| Headache | 3.0 (24) |
| Ovarian Hyperstimulation Syndrome | 2.4 (19) |
| Vaginal Bleeding | 1.8 (14) |
| Injection Site Reaction | 1.1 (9) |
| Nausea | 1.1 (9) |
| Abdominal Pain (gastrointestinal) | 1.0 (8) |
During post-marketing surveillance, rare cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported (see PRECAUTIONS).
Congenital AnomaliesOngoing clinical follow-up studies of 283 newborns of women administered Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) were reviewed. There were three neonates with major congenital anomalies and 18 neonates with minor congenital anomalies. The major congenital anomalies were: hydrocephalus/meningocele, omphalocele, and Beckwith-Wiedemann Syndrome. The minor congenital anomalies were: nevus, skin tags, sacral sinus, hemangioma, torticollis/asymmetric skull, talipes, supernumerary digit finger, hip subluxation, torticollis/high palate, occiput/abnormal hand crease, hernia umbilicalis, hernia inguinalis, hydrocele, undescended testis, and hydronephrosis. The causal relationship between these congenital anomalies and Ganirelix Acetate Organon Acetate is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, progesterone) may confound ART (Assisted Reproductive Technology) procedures.
The safety of Ganirelix Acetate Organon Injection (ganirelix) was evaluated in two randomized, parallel-group, multicenter controlled clinical studies. Treatment duration for Ganirelix Acetate Organon ranged from 1 to 14 days. Table IV represents adverse events (AEs) from first day of Ganirelix Acetate Organon administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in Ganirelix Acetate Organon-treated subjects without regard to causality.
TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in Ganirelix Acetate Organon-treated subjects). Completed controlled clinical studies (All-subjects-treated group).
| Adverse Events Occurring in ≥ 1% | Ganirelix Acetate Organon N=794 % (n) |
| Abdominal Pain (gynecological) | 4.8 (38) |
| Death Fetal | 3.7 (29) |
| Headache | 3.0 (24) |
| Ovarian Hyperstimulation Syndrome | 2.4 (19) |
| Vaginal Bleeding | 1.8 (14) |
| Injection Site Reaction | 1.1 (9) |
| Nausea | 1.1 (9) |
| Abdominal Pain (gastrointestinal) | 1.0 (8) |
During post-marketing surveillance, rare cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported (see PRECAUTIONS).
Congenital AnomaliesOngoing clinical follow-up studies of 283 newborns of women administered Ganirelix Acetate Organon Injection (ganirelix) were reviewed. There were three neonates with major congenital anomalies and 18 neonates with minor congenital anomalies. The major congenital anomalies were: hydrocephalus/meningocele, omphalocele, and Beckwith-Wiedemann Syndrome. The minor congenital anomalies were: nevus, skin tags, sacral sinus, hemangioma, torticollis/asymmetric skull, talipes, supernumerary digit finger, hip subluxation, torticollis/high palate, occiput/abnormal hand crease, hernia umbilicalis, hernia inguinalis, hydrocele, undescended testis, and hydronephrosis. The causal relationship between these congenital anomalies and Ganirelix Acetate Organon is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, progesterone) may confound ART (Assisted Reproductive Technology) procedures.
Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate Organon Injection (ganirelix) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
The pharmacokinetic parameters of single and multiple injections of Ganirelix Acetate Organon Acetate Injection in healthy adult females are summarized in Table I. Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of Ganirelix Acetate Organon Acetate are dose-proportional in the dose range of 125 to 500 µg.
TABLE I: Mean (SD) pharmacokinetic parameters of 250 µg of Ganirelix Acetate Organon Acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days.
| tmax h | t1/2 h | Cmax ng/mL | AUC ng•h/mL | CL/F L/h | Vd/F L | |
| Ganirelix Acetate Organon Acetate single dose | 1.1 (0.3) | 12.8 (4.3) | 14.8 (3.2) | 96 (12) | 2.4 (0.2)† | 43.7 (11.4)† |
| Ganirelix Acetate Organon Acetate multiple dose | 1.1 (0.2) | 16.2 (1.6) | 11.2 (2.4) | 77.1 (9.8) | 3.3 (0.4) | 76.5 (10.3) |
| tmax Time to maximum concentration t1/2 Elimination half-life Cmax Maximum serum concentration AUC Area under the curve; Single dose: AUC0-&inifn;; multiple dose: AUC0-24 Vd Volume of distribution † Based on intravenous administration CL Clearance = Dose/AUC0-&inifn; F Absolute bioavailability |
Ganirelix Acetate Organon Acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of Ganirelix Acetate Organon Acetate following a single 250 µg subcutaneous injection to healthy female volunteers is 91.1%
DistributionThe mean (SD) volume of distribution of Ganirelix Acetate Organon Acetate in healthy females following intravenous administration of a single 250 µg dose is 43.7 (11.4) liters (L). In vitro protein binding to human plasma is 81.9%.
MetabolismFollowing single dose intravenous administration of radiolabeled Ganirelix Acetate Organon Acetate to healthy female volunteers, Ganirelix Acetate Organon Acetate is the major compound present in the plasma (50-70% of total radioactivity in the plasma) up to 4 hours and urine (17.1-18.4% of administered dose) up to 24 hours. Ganirelix Acetate Organon Acetate is not found in the feces. The 1-4 peptide and 1-6 peptide of Ganirelix Acetate Organon Acetate are the primary metabolites observed in the feces.
ExcretionOn average, 97.2% of the total radiolabeled Ganirelix Acetate Organon Acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [14C]-Ganirelix Acetate Organon Acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.
The pharmacokinetic parameters of single and multiple injections of Ganirelix Acetate Injection in healthy adult females are summarized in Table I. Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of Ganirelix Acetate Organon are dose-proportional in the dose range of 125 to 500 µg.
TABLE I: Mean (SD) pharmacokinetic parameters of 250 µg of Ganirelix Acetate Organon following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days.
| tmax h | t1/2 h | Cmax ng/mL | AUC ng•h/mL | CL/F L/h | Vd/F L | |
| Ganirelix Acetate Organon single dose | 1.1 (0.3) | 12.8 (4.3) | 14.8 (3.2) | 96 (12) | 2.4 (0.2)† | 43.7 (11.4)† |
| Ganirelix Acetate Organon multiple dose | 1.1 (0.2) | 16.2 (1.6) | 11.2 (2.4) | 77.1 (9.8) | 3.3 (0.4) | 76.5 (10.3) |
| tmax Time to maximum concentration t1/2 Elimination half-life Cmax Maximum serum concentration AUC Area under the curve; Single dose: AUC0-&inifn;; multiple dose: AUC0-24 Vd Volume of distribution † Based on intravenous administration CL Clearance = Dose/AUC0-&inifn; F Absolute bioavailability |
Ganirelix Acetate Organon is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of Ganirelix Acetate Organon following a single 250 µg subcutaneous injection to healthy female volunteers is 91.1%
DistributionThe mean (SD) volume of distribution of Ganirelix Acetate Organon in healthy females following intravenous administration of a single 250 µg dose is 43.7 (11.4) liters (L). In vitro protein binding to human plasma is 81.9%.
MetabolismFollowing single dose intravenous administration of radiolabeled Ganirelix Acetate Organon to healthy female volunteers, Ganirelix Acetate Organon is the major compound present in the plasma (50-70% of total radioactivity in the plasma) up to 4 hours and urine (17.1-18.4% of administered dose) up to 24 hours. Ganirelix Acetate Organon is not found in the feces. The 1-4 peptide and 1-6 peptide of Ganirelix Acetate Organon are the primary metabolites observed in the feces.
ExcretionOn average, 97.2% of the total radiolabeled Ganirelix Acetate Organon dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [14C]-Ganirelix Acetate Organon. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.
Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with Ganirelix Acetate Organon Acetate, pregnancy must be excluded. Safe use of Ganirelix Acetate Organon Acetate during pregnancy has not been established (see CONTRAINDICATIONS and PRECAUTIONS).
PRECAUTIONS GeneralCases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during post-marketing surveillance (see ADVERSE REACTIONS).
The packaging of this product contains natural rubber latex which may cause allergic reactions.
Laboratory TestsA neutrophil count ≥ 8.3 ( x 109/L) was noted in 11.9% (up to 16.8 x 109/L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined.
Carcinogenesis and Mutagenesis, Impairment of FertilityLong-term toxicity studies in animals have not been performed with Ganirelix Acetate Organon Acetate Injection to evaluate the carcinogenic potential of the drug. Ganirelix Acetate Organon Acetate did not induce a mutagenic response in the Ames test (S. typhimurium and E. coli) or produce chromosomal aberrations in in vitro assay using Chinese Hamster Ovary cells.
Pregnancy Pregnancy Category XGanirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 µg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), Ganirelix Acetate Organon Acetate increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with Ganirelix Acetate Organon Acetate during pregnancy and lactation.
The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotrophic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see CONTRAINDICATIONS).
Nursing MothersGanirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) should not be used by lactating women. It is not known whether this drug is excreted in human milk.
Geriatric UseClinical studies with Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) did not include a sufficient number of subjects aged 65 and over.
WARNINGSGanirelix Acetate Organon Injection (ganirelix) should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with Ganirelix Acetate Organon, pregnancy must be excluded. Safe use of Ganirelix Acetate Organon during pregnancy has not been established (see CONTRAINDICATIONS and PRECAUTIONS).
PRECAUTIONS GeneralCases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during post-marketing surveillance (see ADVERSE REACTIONS).
The packaging of this product contains natural rubber latex which may cause allergic reactions.
Laboratory TestsA neutrophil count ≥ 8.3 ( x 109/L) was noted in 11.9% (up to 16.8 x 109/L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the Ganirelix Acetate Organon Injection (ganirelix) group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined.
Carcinogenesis and Mutagenesis, Impairment of FertilityLong-term toxicity studies in animals have not been performed with Ganirelix Acetate Injection to evaluate the carcinogenic potential of the drug. Ganirelix Acetate did not induce a mutagenic response in the Ames test (S. typhimurium and E. coli) or produce chromosomal aberrations in in vitro assay using Chinese Hamster Ovary cells.
Pregnancy Pregnancy Category XGanirelix Acetate Organon Injection (ganirelix) is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 µg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), Ganirelix Acetate Organon increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with Ganirelix Acetate Organon during pregnancy and lactation.
The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotrophic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see CONTRAINDICATIONS).
Nursing MothersGanirelix Acetate Organon Injection (ganirelix) should not be used by lactating women. It is not known whether this drug is excreted in human milk.
Geriatric UseClinical studies with Ganirelix Acetate Organon Injection (ganirelix) did not include a sufficient number of subjects aged 65 and over.
After initiating FSH therapy on Day 2 or 3 of the cycle, Ganirelix Acetate Organon Acetate Injection (Ganirelix Acetate Organon) 250 µg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with Ganirelix Acetate Organon Acetate should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome).
Directions for Using Ganirelix Acetate Organon Acetate Injection
After initiating FSH therapy on Day 2 or 3 of the cycle, Ganirelix Acetate Organon Injection (ganirelix) 250 µg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with Ganirelix Acetate Organon should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome).
Directions for Using Ganirelix Acetate Organon Injection
